FDA Clears At-Home HPV Screening Tool - Summary - MDSpire
FDA & Government News

FDA Clears At-Home HPV Screening Tool

Self-collection approach aims to expand screening access

Share

The FDA has approved the Onclarity HPV self-collection kit and the BD Onclarity HPV Assay for at-home cervical cancer screening, enhancing accessibility. This initiative addresses the issue of unscreened patients, as about 60% of cervical cancer cases occur among those not following screening guidelines. The self-collection kit enables individuals to send samples for testing of high-risk HPV types, facilitating earlier identification and timely care management. Insurance coverage is expected, with the kit available by prescription soon.

Original Source(s)

FDA Clears At-Home HPV Screening Tool

  • by Kathryn Wighton

  • April 8, 2026

Related Content

‘4-Minute Rule’ Guides Cesarean Timing

Physiologic mechanisms and team coordination inform management during maternal cardiac arrest

Hidden Pain After Mastectomy?

Chronic postsurgical pain affects many patients but is often underdiagnosed and undertreated.

The Hidden Differences Between Oral Contraceptives

National adverse-event and prescribing data suggest oral contraceptive formulations differ in reported acne, migraine, anxiety, and depression